Your session is about to expire
What is Delstrigo
LamivudineThe Generic name of this drug
Treatment SummaryTenofovir disoproxil fumarate, sold under the brand name Viread, is a medication used to treat HIV and hepatitis B. It belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), and is meant to be taken in combination with other medications. Tenofovir disoproxil was approved by the FDA in 2001.
Epiviris the brand name
Delstrigo Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Epivir
Lamivudine
1995
178
Approved as Treatment by the FDA
Lamivudine, otherwise called Epivir, is approved by the FDA for 3 uses which include Chronic Hepatitis B Infection and HIV .Chronic Hepatitis B Infection
HIV
Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with Abacavir
HIV
Effectiveness
How Delstrigo Affects PatientsTenofovir is used to treat HIV-1 and Hepatitis B infections by preventing the virus from making copies of itself. Laboratory tests have shown that it is effective against HIV-1 at concentrations between 0.04 μM to 8.5 μM. Tenofovir has been found to work well in combination with other drugs used to treat HIV-1, such as nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors, as well as protease inhibitors. Clinical studies have also confirmed that it can effectively fight HIV-1 in cell cultures.
How Delstrigo works in the bodyTenofovir is an antiretroviral medicine used to reduce the amount of HIV in the body. It works by blocking a special enzyme that HIV needs to reproduce. When this enzyme is blocked, the virus can't make as many copies of itself. Tenofovir is absorbed and converted to its active form which is a type of chemical called a nucleotide analog. This chemical then binds to the HIV enzyme and stops it from working. It also prevents the virus from making DNA. In some cases, HIV can become resistant to tenofovir, meaning that it is not as effective at stopping the virus from reproducing
When to interrupt dosage
The suggested dosage of Delstrigo is based on the identified affliction, including Anti-Retroviral Agents, High Risk Patients and Chronic Hepatitis B. The measure of dosage fluctuates, depending on the procedure of delivery (e.g. Tablet or Tablet, film coated) provided in the table below.Condition
Dosage
Administration
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Treatment Naive
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
HIV
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Anti-Retroviral Agents
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Chronic Hepatitis B Infection
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
treatment failure
150.0 mg, 100.0 mg, , 5.0 mg/mL, 300.0 mg, 10.0 mg/mL, 30.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Solution, Solution - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral
Warnings
There are 20 known major drug interactions with Delstrigo.Common Delstrigo Drug Interactions
Drug Name
Risk Level
Description
Aclidinium
Minor
Lamivudine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
Acrivastine
Minor
Lamivudine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Albutrepenonacog alfa
Minor
Lamivudine may decrease the excretion rate of Albutrepenonacog alfa which could result in a higher serum level.
Allylestrenol
Minor
Lamivudine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.
Almasilate
Minor
Lamivudine may decrease the excretion rate of Almasilate which could result in a higher serum level.
Delstrigo Toxicity & Overdose RiskWhen it comes to breastfeeding, the Centers for Disease Control and Prevention recommend that mothers with HIV-1 not breastfeed their infants to prevent transmission. Mothers should not breastfeed if they are taking tenofovir disoproxil. There have been no studies done on pregnant women taking tenofovir disoproxil, but studies done on rats and rabbits showed no signs of harm to the fetus at doses up to 14 and 19 times the recommended human dose. To monitor the effects of this drug on pregnant women, a registry has been created for healthcare providers to register patients. Tenofov
Delstrigo Novel Uses: Which Conditions Have a Clinical Trial Featuring Delstrigo?
Currently, 46 active clinical trials are assessing the potential of Delstrigo to replace a current antiretroviral treatment regimen for certain virologically suppressed (HIV1 RNA <50 copies/mL) adult patients on a stable regimen at the start of therapy, as well as in treating Chronic Hepatitis B and HIV (Human Immunodeficiency Virus).Condition
Clinical Trials
Trial Phases
HIV
132 Actively Recruiting
Phase 2, Phase 1, Not Applicable, Phase 3, Phase 4, Early Phase 1
HIV
45 Actively Recruiting
Phase 2, Phase 3, Early Phase 1, Phase 1, Not Applicable, Phase 4
Chronic Hepatitis B Infection
8 Actively Recruiting
Phase 3, Phase 2, Phase 1
Treatment Naive
0 Actively Recruiting
treatment failure
0 Actively Recruiting
Anti-Retroviral Agents
0 Actively Recruiting
Delstrigo Reviews: What are patients saying about Delstrigo?
2Patient Review
6/25/2021 I gained weight when I switched to delstrigo, and my hiv 1rna levels increased.
Patient Q&A Section about delstrigo
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Delstrigo?
"The most common side effects of Delstrigo include abnormal dreams, difficulty sleeping, nightmares, depression, headaches, dizziness, drowsiness, coughing, an irritated or runny nose, nausea, diarrhea, abdominal pain, vomiting, hair loss, rashes, muscle disorders, fatigue, and fever."
Answered by AI
What does Delstrigo do?
"The DELSTRIGO prescription medication is used to treat HIV-1 infection in adults who have not received HIV-1 medicines in the past, or to replace their current HIV-1 medicines. This decision is made by the patient's healthcare provider after determining that the patient meets certain requirements."
Answered by AI
Who manufactures Delstrigo?
"The European Commission red lighted Merck's DELSTRIGO (doravirine / lamivudine / tenofovir disoproxil fumarate), a once-daily fixed-dose combination tablet as a complete regimen and PIFELTRO (doravirine), an NNRTI, both for the treatment of HIV-1 in [the European Union]."
Answered by AI
How good is Delstrigo?
"In a study of 728 adults, 84% of those treated with Delstrigo had undetectable HIV levels in their blood (fewer than 40 copies/ml) after 48 weeks, compared to 80% of those given a combination of efavirenz, emtricitabine, and tenofovir disoproxil."
Answered by AI